[1] HAN B,ZHENG R,ZENG H,et al.Cancer incidence and mortality in China,2022[J].JNCC,2024,4(1):47-53.
[2] KRATZER T B,BANDI P,FREEDMAN N D,et al.Lung cancer statistics,2023[J].Cancer,2024,130(8):1330-1348.
[3] ZHU W,LOVE K,GRAY S W,et al.Liquid biopsy screening for early detection of lung cancer:current state and future directions[J].Clin Lung Cancer,2023,24(3):209-217.
[4] 郑琳琳,刘振荣,李海洋,等.端粒酶逆转录酶在肝细胞肝癌中的表达及其与预后和免疫细胞浸润的关系[J].中国肿瘤临床与康复,2023,30(8):499-506.
[5] 刘云,高登鹏,徐亚飞,等.结直肠癌组织中CDC5L、DDX21及端粒酶的表达与临床意义[J].西部医学,2023,35(3):348-353.
[6] CHEN G,WANG S,ZHANG Q,et al.Circulating TERT serves as the novel iagnostic and prognostic biomarker for the resectable NSCLC[J].Cancer Cell International,2024,24(1):420-428.
[7] GHANIM G E,FOUNTAIN A J,VAN ROON A M,et al.Structure of human telomerase holoenzyme with bound telomeric DNA[J].Nature,2021,593(7859):449-453.
[8] YUAN X,DAI M,XU D.Telomere-related markers for cancer[J].Curr Top Med Chem,2020,20(6):410-432.
[9] 张晓娜,郭鸿斌,程龙,等.敲除端粒酶TERC基因的人Calu3细胞模型的构建及功能验证[J].中国细胞生物学学报,2022,44(5):848-855.
[10] SUBASRI M,SHOOSHTARI P,WATSON A J,et al.Analysis of TERT isoforms across TCGA,GTEx and CCLE datasets[J].Cancers,2021,13(8):1853-1874.
[11] ROAKE C M,ARTANDI S E.Regulation of human telomerase in homeostasis and disease[J].Nat Rev Mol Cell Biol,2020,21(7):384-397.
[12] NOUREEN N,WU S,LV Y,et al.Integrated analysis of telomerase enzymatic activity unravels an association with cancer stemness and proliferation[J].Nat Commun,2021,12(1):139-150.
[13] GOMATOU G,MASAOUTIS C,VAMVAKARIS I,et al.Differential immunohistochemical expression of hTERT in lung cancer patients with and without idiopathic pulmonary fibrosis[J].Pulmonology,2024,30(3):214-221.
[15] LIU N,GUO X,LIU J,et al.Role of telomerase in the tumour microenvironment[J].Clin Exp Pharmacol Physiol,2020,47(3):357-364.
[16] TEPLITZ G M,PASQUIER E,BONNELL E,et al.A mechanism for telomere-specific telomere length regulation[J/OL].bioRxiv,2024,doi:10.1101/2024.06.12.598646.bioRxiv,2024.
[17] POOS A,SCHROEDER C,JAISHANKAR N,et al.PITX1 is a regulator of TERT expression in prostate cancer with prognostic power[J].Cancers,2022,14(5):1267-1290.
[18] 詹颖婷,刘帅莹,于佳乐,等.δ-catenin通过增强肿瘤细胞的干性特征和端粒酶活性促进肺癌的恶性表型[J].现代肿瘤医学,2022,30(11):1977-1982.
[19] QIN Y,CHEN W,XIAO Y,et al.RFPL3 and CBP synergistically upregulate hTERT activity and promote lung cancer growth[J].Oncotarget,2015,6(29):27130-27145.
[20] ROTEM O,UZIEL O,ZER A,et al.Blood-derived exosomal hTERT mRNA in patients with lung cancer:characterization and correlation with response to therapy[J].Ann Oncol,2021,32:372.
[21] 邓日强,万仁平,肖芸,等.端粒酶逆转录酶mRNA的表达与非小细胞癌患者诊断和预后的相关性分析[J].河北医药,2019,41(1):33-36.
[22] 吴瑞锋,王律,张志强,等.非小细胞肺癌患者外周血白细胞端粒酶活性对预后的影响[J].中国临床医生杂志,2019,47(11):1287-1290.
[23] MA D,HE Y,BAI H,et al.A novel near-infrared fluorescent probe for specific imaging of telomerase reverse transcriptase in vivo[J].Microchem J,2024,196:109547-109555.
[24] CHAE M,LEE H J,PARK H J,et al.Different role of TRF1 and TRF2 expression in non-small cell lung cancers[J].OncoTargets Ther,2024,17:463-469.
[25] GU W,LI H S,SUN L,et al.The RNA-binding protein CMSS1 promotes the progression of non-small cell lung cancer by regulating the telomerase protein subunit hTERT[J].Life Sciences,2024,361:123321-123336.
[26] LIU M,ZHANG Y,JIAN Y,et al.The regulations of telomerase reverse transcriptase (TERT) in cancer[J].Cell Death Dis,2024,15(1):90-102.
[27] SHARMA S,CHOWDHURY S.Emerging mechanisms of telomerase reactivation in cancer[J].Trends Cancer,2022,8(8):632-641.
[28] TORNESELLO M L,CERASUOLO A,STARITA N,et al.Reactivation of telomerase reverse transcriptase expression in cancer:the role of TERT promoter mutations[J].Front Cell Dev Bio,2023,11:1286683-1286696.
[29] SHEPELEV M V,KALINICHENKO S V,SAAKIAN E K,et al.Xenobiotic Response Elements (XREs) from human CYP1A1 gene enhance the hTERT promoter activity[J].Dokl Biochem Biophy,2019,485(1):150-152.
[30] MIAO B,ZHANG C,STROH N,et al.Transcription factor TFE3 enhances cell cycle and cancer progression by binding to the hTERT promoter[J].Cancer Commun,2021,41(12):1423-1426.
[31] ZOHUD B A,GUO P,ZOHUD B A,et al.Importin 13 promotes NSCLC progression by mediating RFPL3 nuclear translocation and hTERT expression upregulation[J].Cell Death Dis,2020,11(10):879-894.
[32] OTT P,ARAÚZO-BRAVO M J,HOFFMANN M J,et al.Differential DNA methylation of THOR and hTAPAS in the regulation of hTERT and the diagnosis of cancer[J].Cancers,2022,14(18):4384-4398.
[33] 曾平,郭鹏翔,骆横.人端粒酶逆转录酶在肿瘤转录调控机制中的研究进展[J].实用肿瘤学杂志,2023,37(1):68-72.
[34] SARNE V,HUTER S,BRAUNMUELLER S,et al.Promoter methylation of selected genes in non-small-cell lung cancer patients and cell lines[J].Int J Mol Sci,2020,21(13):4595-4671.
[35] YANG L,LI N,WANG M,et al.Tumorigenic effect of TERT and its potential therapeutic target in NSCLC (Review)[J].Oncol Rep,2021,46(2):182-194.
[36] WERR L,BARTENHAGEN C,ROSSWOG C,et al.TERT expression and clinical outcome in pulmonary carcinoids[J].JCO,2024,43(2):214-225.
[37] PARK Y J,KIM E K,BAE J Y,et al.Human telomerase reverse transcriptase (hTERT) promotes cancer invasion by modulating cathepsin D via early growth response (EGR)-1[J].Cancer Lett,2016,370(2):222-231.
[38] PIÑEIRO-HERMIDA S,BOSSO G,SÁNCHEZ-VÁZQUEZ R,et al.Telomerase deficiency and dysfunctional telomeres in the lung tumor microenvironment impair tumor progression in NSCLC mouse models and patient-derived xenografts[J].Cell Death Differ,2023,30(6):1585-1600.
[39] MATSUDA Y,YAMASHITA T,YE J,et al.Phosphorylation of hTERT at threonine 249 is a novel tumor biomarker of aggressive cancer with poor prognosis in multiple organs[J].Journal of Pathology,2022,257(2):172-185.
[40] REMCO M,HES B,AURELIEN V,et al.Prognostic value of hTERT mRNA expression in surgical samples of lung cancer patients:the European early lung cancer project[J].Int J Oncol,2010,37(2):455-461.
[41] MARZENA Z,KATARZYNA D,KRZYSZTOF B,et al.Clinical and prognostic value of hTERT MRNA expression in patients with non-small-cell lung cancer[J].Acta Biochim Pol,2017,64(4):641-646.
[42] YUAN P,HUANG S,BAO F C,et al.Discriminating association of a common telomerase reverse transcriptase promoter polymorphism with telomere parameters in non-small cell lung cancer with or without epidermal growth factor receptor mutation[J].Eur J Cancer,2019,120:10-19.
[43] YANG L,WANG M,LI N,et al.TERT mutations in non-small cell lung cancer:clinicopathologic features and prognostic implications[J].Clin Med Insights:Oncol,2023,17:1-8.
[44] STÖGBAUER L,STUMMER W,SENNER V,et al.Telomerase activity,TERT expression,hTERT promoter alterations,and alternative lengthening of the telomeres (ALT) in meningiomas-a systematic review[J].Neurosurgical Review,2020,43(3):903-910.
[45] CHEN E,BAO Z,ZHEN H,et al.Template-ready PCR method for detection of human telomerase reverse transcriptase mRNA in sputum[J].Anal Biochem,2019,577:34-41.
[46] ZHANG W,DUAN X,ZHANG Z,et al.Combination of CT and telomerase+circulating tumor cells improves diagnosis of small pulmonary nodules[J].Clin Med,2021,6(11):148182-148197.
[47] WEN L,ZHAO C,SONG J,et al.CRISPR/Cas9-mediated TERT disruption in cancer cells[J].Int J Mol Sci,2020,21(2):653-665. |
